DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

$20.97
-0.12 (-0.57%)
As of Mar 24, 9:59 PM ET ·
Financial Highlights (FY 2025)
Revenue
267.02M
Net Income
59.27M
Gross Margin
58.3%
Profit Margin
22.2%
Rev Growth
-5.4%
D/E Ratio
0.51
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 58.3% 58.3% 58.3%
Operating Margin 23.6% 24.2% 21.7%
Profit Margin 22.2% 19.8% 18.0%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 267.02M 243.47M 233.58M
Gross Profit 155.80M 142.05M 136.28M
Operating Income 62.89M 58.96M 50.72M
Net Income 59.27M 48.26M 42.10M
Gross Margin 58.3% 58.3% 58.3%
Operating Margin 23.6% 24.2% 21.7%
Profit Margin 22.2% 19.8% 18.0%
Rev Growth -5.4% -1.1% +3.4%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 712.45M 763.70M 731.12M
Total Equity 1.40B 1.35B 1.36B
D/E Ratio 0.51 0.57 0.54
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 80.54M 76.00M 71.04M
Free Cash Flow 42.58M 43.55M 31.33M